Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ion Transport Protein Linked to Brain Cancer Cell Migration and Invasion

By LabMedica International staff writers
Posted on 22 May 2012
Print article
By elaborating the molecular interactions of the ion transport protein NKCC1(Na+-K+-Cl-cotransporter 1) cancer researchers have garnered new insights into the forces that drive glioblastoma multiforme cell migration and invasion.

Glioblastoma multiforme (GBM) is an aggressive brain tumor, fatal within one year from diagnosis in most patients despite intensive treatment with surgery, radiation, and chemotherapy. The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment.

NKCC proteins are membrane transport proteins that transport sodium (Na), potassium (K), and chloride (Cl) ions across the cell membrane. They maintain electroneutrality by moving two positively charged solutes (sodium and potassium) alongside two parts of a negatively charged solute (chloride). NKCC1 is known to regulate cell volume and intracellular chloride concentration and to play an important role in brain tumor-cell invasion.

Researchers at Johns Hopkins University (Baltimore, MD, USA) investigated (1) whether the expression of NKCC1 in human tumors correlated with tumor grade; (2) whether NKCC1 affected cell contractility and migration; (3) whether NKCC1 could have an effect on the interaction between the cells and the cells' adhesion substratum; and (4) whether a signaling mechanism involved in the regulation of NKCC1 by promigratory factors existed in GB cells.

Results published in the May 1, 2012, online edition of the journal PLoS Biology revealed that in addition to its conventional function as an ion transporter, NKCC1 also interacted with the cytoskeleton and affected brain tumor-cell migration by acting as an anchor that transduced contractile forces from the plasma membrane to the extracellular matrix en route to cell migration. Regulation of NKCC1 by a family of unconventional enzymes, the WNK kinases, was an important factor that affected the activity of NKCC1 and determined the invasive ability of brain tumor cells. NKCC1 expression correlated with in vivo glioma aggressiveness, and the transporter activity modulated migration speed and invasiveness of cells derived from various human GBs.

“The biggest challenge in brain cancer is the migration of cancer cells. We cannot control it,” said senior author Dr. Alfredo Quinones-Hinojosa, associate professor of neurosurgery and oncology at Johns Hopkins University. “If we could catch these cells before they take off into other parts of the brain, we could make malignant tumors more manageable, and improve life expectancy and quality of life. This discovery gives us hope and brings us closer to a cure.”

Related Links:
Johns Hopkins University



Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centrifuge
Hematocrit Centrifuge 7511M4
New
Silver Member
ACTH Assay
ACTH ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.